Modular tissue securement systems

Information

  • Patent Grant
  • 9592046
  • Patent Number
    9,592,046
  • Date Filed
    Friday, May 30, 2014
    10 years ago
  • Date Issued
    Tuesday, March 14, 2017
    7 years ago
Abstract
A system and method are disclosed for the securement of tissue and in particular for placement of a tongue base suspension fiber for the treatment of obstructive sleep apnea. The system incorporates disposable connectors with releasable needles to facilitate the placement of fibers with minimal increase in suture site dilation or trauma.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


This invention generally relates to systems to secure tissue, more particularly to tissue securement systems for treatment of obstructive sleep apnea.


2. Related Art


Obstructive sleep apnea (OSA) is caused by a blockage of the airway, which usually occurs when the soft tissue in the throat collapses and closes during sleep. According to the National Institutes of Health, OSA affects more than twelve million Americans. During each apnea event, the brain briefly arouses the sufferer in order to initiate the resumption of breathing. This type of sleep, however, is extremely fragmented and of poor quality. When left untreated, OSA may result in high blood pressure, cardiovascular disease, weight gain, impotency, headaches, memory problems, job impairment, and motor vehicle crashes. Despite the seriousness of OSA, a general lack of awareness among the public and healthcare professionals results in the vast majority of OSA sufferers remaining undiagnosed and untreated.


In the human body, an air filled space between the nasal cavity and the larynx is referred to as the upper airway. The most critical part of the upper airway associated with sleep disorders is the pharynx. The pharynx has three different anatomical levels. The nasopharynx is the upper portion of the pharynx located in the back of the nasal cavity. The oropharynx is the intermediate portion of the pharynx containing the soft palate, the epiglottis, and the curve at the back of the tongue. The hypopharynx is the lower portion of the pharynx located below the soft tissue of the oropharynx. The oropharynx is the section of the pharynx that is most likely to collapse due to the high prevalence of soft tissue structure, which leaves less space for airflow. The hypopharynx lies below the aperture of the larynx and behind the larynx, and extends to the esophagus.


As is well known to those skilled in the art, the soft palate and the tongue are both flexible structures. The soft palate provides a barrier between the nasal cavity and the mouth. In many instances, the soft palate is longer than necessary and it extends a significant distance between the back of the tongue and the posterior pharyngeal wall.


Although the muscles relax throughout the body during sleep, most of the muscles of the respiratory system remain active. During inhalation, the diaphragm contracts and causes negative pressure to draw air into the nasal cavity and the mouth. The air then flows past the pharynx, through the trachea and into the lungs. The negative pressure causes the tissue of the upper airway to deform slightly, which narrows the airway passage. In apneic patients, the soft palate, the tongue, and/or the epiglottis collapse against the posterior pharyngeal wall to block airflow into the trachea. As the airway narrows, airflow through the pharynx becomes turbulent which causes the soft palate to vibrate, generating a sound commonly known as snoring.


During sleep, humans typically experience brief obstructions of airflow and/or small decreases in the amount of airflow into the trachea and lungs. An obstruction of airflow for more than ten seconds is referred to as apnea. A decrease in airflow by more than fifty percent is referred to as hypopnea. The severity of sleep disorders is measured by the number of apneas and hypopneas that occur during every hour of sleep.


If apnea or hypopnea occurs more than five times per hour, most medical personnel diagnose the individual as having an upper airway resistance problem. Many of these patients often exhibit symptoms related to sleep disorders including sleepiness during the day, depression, and difficulty concentrating.


Individuals having ten or more episodes of apnea or hypopnea during every hour of sleep are officially classified as having obstructive sleep apnea syndrome. As the airway is obstructed, the individual makes repeated attempts to force inhalation. Many of these episodes are silent and are characterized by movements of the abdomen and chest wall as the individual strains to draw air into the lungs. Typically, episodes of apnea may last a minute or more. During this time, oxygen levels in the blood will decrease. Ultimately, the obstruction may be overcome by the individual generating a loud snore or awakening with a choking feeling.


When an individual is awake, the back of the tongue and the soft palate maintain their shape and tone due to their respective internal muscles. As a result, the airway through the pharynx remains open and unobstructed. During sleep, however, the muscle tone decreases and the posterior surface of the tongue and the soft palate become more flexible and distensible. Without normal muscle tone to keep their shape and to keep them in place either alone or as a group, the posterior surface of the tongue, the epiglottis, and the soft palate tend to easily collapse to block the airway.


U.S. Pat. No. 7,367,340 describes one approach to treat sleep apnea and is directed to the use of an element that is anchored to the mandible and is capable of applying force within the tongue to prevent the tongue from collapsing during sleep. In the embodiments described, the device consists of an element that is attached to the mandible though drilling of the mandible to provide a rigid point of fixation. The method of attachment risks damaging the dental anatomy and nerve structures within the mandible.


A commercial implant system, sold under the trademark REPOSE™ by InfluENT of Concord, N.H., uses a titanium screw that is inserted into the posterior aspect of the mandible at the floor of the mouth. A loop of suture is passed through the tongue base and attached to the mandibular bone screw. The REPOSE™ procedure achieves a suspension or hammock of the tongue base making it less likely for the base of the tongue to prolapse during sleep. Due to the high activity of the tongue during wakefulness, however, the suture component of this device may act as a cutting element within the tongue, causing device trans-location and ultimately a loss of efficacy of the procedure thereby requiring subsequent removal. Additionally, the fiber is placed within the tongue through the combination of a sterile and non-sterile approach. An incision is made within the sub-mental space to provide access to the infra-mandibular region to place the screw. Once the screw is attached to the mandible, the fiber element is passed into the tongue through the sub-mental musculature, through the genioglossus and exits out of the mucosal surface of the tongue into the contaminated oral cavity. This passage is accomplished through the use of a linear designed suture passer that grasps the fiber, through the use of a jaw like element, and forces it through the tongue in a straight path. Upon exiting in the oral cavity, the fiber is then passed laterally in a sub mucosal pass through the original puncture formed by the curved suture passer which is essentially an eyed needle.


The use of the eyed needle results in the folding of the fiber in half about the eyelet of the needle, thereby increasing, in an irregular fashion, the projected diameter/dissecting cross section of the device. This increase in projected dissection surfaces results in the creation of a larger hole than is necessary for the single strand of fiber that is to be deposited within the tissue tract.


Furthermore, the use of the jawed type linear suture passer also results in an increased projected cross sectional dissecting surface. The fiber is laid into the jaw and is clamped. In the best case scenario, the jaw resultant projected dissecting tissue surface consists of the cross sectional area of the fiber lying alongside the cross sectional area of the shaft of the linear suture passer.


Another commercially available tongue suspension device, developed by ASPIRE Medical, is named the ADVANCE System. It's similar to the REPOSE suture suspension system for the tongue base in that it utilizes a bone screw in the mandible, but has the advantage of being adjustable. The device utilizes a flexible shape memory anchor within the tongue that is shaped similar to a grappling hook to engage the tissue within the tongue base. It's placed through a small incision in the sub-mental region and the suture is attached to a spool-like component attached to the mandible. Two to four weeks after healing, a small incision is made under the chin and a screw is turned to tighten the suture, thus pulling the device forward. While the device provides a simplified installation technique from within the sterile space, the anchors may suffer from a high rate of device fracture and failure due to loading within the tongue musculature. Additionally, the risk of damage to the teeth or the nerve roots for the teeth is similar to the RESPOSE bone screw.


In spite of the above advances in tongue suspension devices, there remains a need for a tongue suspension method and suture passer device that enables the passage of fiber with minimal increase in the size of the dissected tunnel formed in the traverse of the fiber.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1
a-c depict elements of one method of a tissue securement system particularly directed toward the threading of fiber through an eyelet of a linear suture passer and the subsequent passing of the threaded fiber through tissue.



FIG. 2 depicts one embodiment of a fiber component of the present invention with eyeleted connectors attached to the ends of the fiber.



FIGS. 3a-3b show embodiments for a releasably connectable needle and suture passer suitable for use with the system of the present invention.



FIG. 4 depicts a releasably engaged needle and fiber approaching tissue to be treated.



FIG. 5 shows the releasably engaged needle and fiber penetrating and exiting tissue.



FIG. 6 depicts the releasably engaged needle of FIG. 5 after being released from a securement fiber.



FIG. 7 illustrates use of a fiber passer deployed through the musculature of the tongue to engage connector end of securement fiber.



FIG. 8 shows engagement of a fiber passer with a connector at one of the ends of securement fiber prior to pulling of the engaged fiber though tissue.



FIG. 9 depicts cutting away of the connectors on the securement fiber ends.





SUMMARY OF THE INVENTION

The present invention relates generally to a system for the securement of tissue comprising:


a) a securement fiber comprising a distal end and a proximal end, the distal end further comprising a distal connector and the proximal end further comprising a proximal connector;


b) a needle comprising a proximal end and a distal end, the distal end further comprising a tissue piercing surface and the proximal end comprising a connector, the connector being releasably engageable with the distal connector of the fiber; and


c) a tissue passer comprising a proximal end and a distal end, the distal end releasably engageable with the distal and proximal connectors of the fiber.


This invention also generally relates to tissue securement methods comprising the steps of:


a) piercing the tissue at a first puncture point with a needle having proximal and distal ends that is attached to a securement fiber, the fiber having a first end and a second end with the attachment of the needle to the fiber occurring at the first end of the fiber and the proximal end of the needle;


b) exiting the tissue at a second puncture point with the needle and securement fiber;


c) releasing the needle from the securement fiber while ensuring that the first and second ends of the fiber remain outside of the tissue at the first and second puncture points;


d) passing a fiber passer from a first entry point through the tissue and out of the tissue at the first puncture point;


e) attaching the distal tip of the fiber passer with the second end of the fiber outside of the tissue at the first puncture point;


f) drawing the fiber attached to the fiber passer through the tissue at the first puncture point by pulling the fiber passer with attached fiber through and out of the first entry point;


g) releasing the fiber from the fiber passer;


h) passing the fiber passer from a second entry point through the tissue and out of the tissue at the second puncture point;


i) attaching the distal tip of the fiber passer with the first end of the fiber outside of the tissue at the second puncture point;


j) drawing the fiber attached to the fiber passer through the tissue at the second puncture point by pulling the fiber passer with attached fiber through and out of the second entry point; and


k) releasing the fiber from the fiber passer; and


l) attaching the fiber ends at the first and second entry points to at least one anchor or tying the fiber ends together.


In preferred embodiments, the systems and methods of this invention relate to securement of the tongue.


The systems and methods of this invention provide at least the following advantages. The connector features on the fiber ends enable the use of releasable needles, eliminates the need to thread the suture through a snaring/eyed needle type arrangement, and minimizes the tissue tract diameter for the later passing of the fiber through tissue. The hook type element on the suture passer allows passes through tissue minimizing the dragging or traumatizing of tissue, permits quick connection to connector features on the fibers ends, and in combination with connector features on the fiber, minimizes the diameter of the tissue tract by ensuring trailing arrangement of the fiber without having the fiber being folded over. The releasable needle enables easy attachment/detachment from the fiber and ensures that the trailing arrangement of the fiber without folding over the fiber to minimize the diameter of the fiber tract through the tissue.


DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

The present invention relates to a tissue securement system that is able to be placed with minimal tissue trauma. The system consists of three key functional components. The system includes a suspension fiber that has modified ends, a releasable needle, and a linear suture passer. The releasable needle and linear suture passer are designed to engage with the modified ends of the suspension fiber.


As used herein, the terms “suture” and “fiber” may be used interchangeably. Additionally, the terms “suture passer”, “fiber passer” and “tissue passer” are intended to be used interchangeably.



FIGS. 1a-1c illustrate a suspension system for securement of tissue 10 (in this case a tongue) that consists of unmodified fiber 20 and suture passer 30. The suture passer 30 illustrated comprises a tapered tip rod with an eyelet. In use, fiber 20 is manually threaded through the eyelet of suture passer 30 within the oral cavity as shown in FIG. 1a. FIG. 1b depicts fiber 20 as it begins to be drawn by suture passer 30 through tissue 10. FIG. 1c is a cross sectional view of FIG. 1b and shows an alternate view of the path that fiber 20 will take as suture passer 30 is drawn through tissue 10. It can be appreciated that within the limited volume of the oral cavity, that the threading of the fiber requires dexterity and patience since the motion of the suture passer is limited. Additionally, it can be seen that the fiber is folded in half about the eyelet thereby increasing the total cross sectional area of the device as it is pulled into the tissue which is a cause for additional trauma as the doubled over fiber is pulled through the tissue.



FIG. 2 illustrates an embodiment of fiber component 20 of the tissue securement system with eyeleted connectors 22 attached. Connectors 22 may be attached to fiber 20 by any conventional way including, but not limited to, crimping the connector to the fiber or by applying an adhesive to the connector and/or the fiber. While eyeleted connectors 22 are shown, one skilled in the art would appreciate that alternative connectors may be used that involve geometries that engage with the releasable needle and suture passer. Non-limiting examples of alternative connectors include conical barbs, flat barbs, male detents, hook-like features, magnetic, or magnetic combined with alignment features such as conical ends and receptor geometries.


While the connectors 22 may be added as separate elements affixed to the ends of the fiber as described above, it would be appreciated by those of skill in the art that connectors 22 may be created at the ends of the fiber directly through any number of means, including but not limited to: i) forming eyelets at the ends of the fiber by bending back an end of the fiber and knotting the fiber end with the fiber to form an eyelet, or, in the case of a multifilament fiber, bending back an end of a multifilament fiber and then splicing the end into and among the filaments of the fiber at a distance sufficient from the end of the fiber to form an eyelet; ii) reshaping the fiber ends through mechanical means such as machining, cutting, bending, etc. or iii) shaping the fiber ends into appropriate geometries through the use of energy based forming such as RF tipping, thermal compression molding, ultrasonic forming and other such methods. For example, in the case of thermoplastic resin based fibers, it may desirable to form the tip of the fiber into a conical barb form or eyelet form for engagement with the suture passer. The free end of the fiber is placed within a forming die cavity that is shaped to the final desired geometry. As pressure is applied to the fiber, the thermoplastic resin exceeds the melting point of the material and is reshaped to the final cavity form. The fiber is subsequently removed from the form after sufficient time has occurred for cooling of the fiber material below its melting point. In the case of thermoset resins, or other non-formable materials, the fiber may be produced as an oversized form. The fiber may then be placed into stamping die that is capable punching out the final form of the fiber with the associated connector end geometry.


Examples of suitable materials for fiber 20 component useful with this invention are any non-absorbable biocompatible suture material. Suitable non-absorbable materials for use in the present invention include, but are not limited to, cotton, linen, silk, polyamides (polyhexamethylene adipamide (nylon 66), polyhexamethylene sebacamide (nylon 610), polycapramide (nylon 6), polydodecanamide (nylon 12) and polyhexamethylene isophthalamide (nylon 61) copolymers and blends thereof), polyesters (e.g. polyethylene terephthalate, polybutyl terephthalate, copolymers and blends thereof), fluoropolymers (e.g. polytetrafluoroethylene and polyvinylidene fluoride) Poly (hexafluoropropylene-VDF), polyaryletherketones, polyolefins (e.g. polypropylene including isotactic and syndiotactic polypropylene and blends thereof, as well as, blends composed predominately of isotactic or syndiotactic polypropylene blended with heterotactic polypropylene and/or polyethylene (such as is described in U.S. Pat. No. 4,557,264 issued Dec. 10, 1985, assigned to Ethicon, Inc., hereby incorporated by reference in its entirety) and combinations thereof.


In the event that a temporary suspension is desirable, such as in the case of trauma, or radical surgical interventions that may cause swelling of the tongue and associated tissues, or in other locations such as urethra suspension, absorbable fibers may be desirable to provide temporary support until edema/swelling has been reduced. Suitable absorbable materials for use as filaments and/or yarns include, but are not limited to, aliphatic polyesters which include but are not limited to homopolymers and copolymers of lactide (which includes lactic acid d-, l- and meso lactide), glycolide (including glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one (including its dimer 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.



FIGS. 3a and 3b show preferred embodiments in which curved needle 40 and linear suture passer 30 are releasably engageable with fiber 20 having eyelet connectors 22. More specifically, FIG. 3a depicts the overall shape of curved needle 40 with an enlarged view of needle 40's proximal end, which in this embodiment is shown to comprise a recessed area with a detent 42 for releasable engagement with eyelet connectors. Similarly, as depicted in FIG. 3b, suture passer 30 is shown with an enlarged view of its distal tip. Suture passer 30's distal tip comprises a tissue piercing point and a recessed portion comprising a detent 32. When used with fiber 20 having eyelet connectors 22, the detent 32 of suture passer 30 will releasably engage connectors 22 and therefore be capable of drawing fiber 20 through tissue.


Non-limiting examples of suture passer tip designs that may be utilized with the previously disclosed fiber connector ends include conical barbs, flat barbs for joining with fibers having eyeleted ends, female detent pockets, eyelets, hook-like features, quick connect type sleeve arrangements, vacuum wells/surfaces, jaw features, passive magnetic tips, energy based magnetic tips, or magnetic combined with alignment features such as conical ends and receptor geometries.


In use, the system of this invention is capable of securing various types of tissue while minimizing trauma to the tissue compared with tissue securement systems of the prior art.


The tissue securement method using the system of this invention is illustrated in the following figures. While the following method is described for securement of a tongue in a tongue suspension procedure, it should be appreciated by one of skill in the art that the method described is equally applicable to securement or suspension of other types of tissue.


Referring to FIG. 4, the tongue suspension procedure is initiated by targeting an area of the tongue to be treated. In this case, lateral passage of the suspension fiber is targeted through the tongue at a location approximately aligned with the median sulcus/circumvallate papillae and is projected to pass through the mucosal surface of the tongue through the use of the releasable needle 40. FIG. 4 illustrates an approach to this surface of the tongue. Specifically, releasable needle 40 engaged with fiber 20 by connector 22, approaches tongue 10.



FIG. 5 shows the path of needle 40 through tongue 10. Needle 40 creates two punctures (P1 and P2) by entering tongue 10 approximately 1 cm lateral to the midline position (P1) and exiting approximately 1 cm lateral on the opposite side of the midline position (P2). In this embodiment, the proximal connector 22 of fiber 20 is not pulled through and remains outside of tongue 10.



FIG. 6 depicts release of needle 40 from fiber connector 22. Once released, fiber 20 is now ready for further steps to secure submucosal tissue of tongue 10 with proximal and distal connectors 22.



FIG. 7 shows a cross sectional view of a portion of human head 50 and a further step in practicing the method of this invention. More specifically, fiber passer 30 is passed from within submental incision 52 through the mylohyoid and genioglossus of tongue 10 to an exit point located within the same puncture P1 created by one of the ends of fiber 20. Referring now to FIG. 8, one of the connector ends 22 of fiber 20 is engaged with the engagement element 32 on the end of the fiber passer 30. In this embodiment, engagement element 32 is in the form of a hooked recess at the tip of fiber passer 30. Once element 32 is engaged with fiber 20, the fiber passer 30 is withdrawn to pull the free end of suspension fiber 20 into puncture P1 of tongue 10, through the tongue's musculature and out of submental incision 52. This step is repeated for the second end of the fiber 20 through puncture P2. It is important to note that the free ends of the suspension fiber 20 may be pulled directly through an anchoring element, either rigid or non-rigid, located in the submental dissection 52 or alternatively they may threaded through the anchor after disengagement with fiber passer 30.


Subsequently, once both ends of fiber 20 are pulled through the musculature and out of submental incision 52, the connector ends 22 are cut off or removed as depicted in FIG. 9.


Once the connectors 22 have been removed, tension is applied to the free ends of fiber 20 to apply the appropriate suspension of the tongue. The free ends of fiber 20 may either be tied to themselves, tied to at least one anchor or may be engaged with a clamping/clipping structure. Common anchoring points for the free ends of fiber 20 include but are not limited to bone or soft tissue. In the case of tongue suspensions, anchoring to the mandible bone such done in the REPOSE and ADVANCE anchoring systems are contemplated. Also anchoring at least one end of the fiber to mesh implanted in soft tissue is contemplated.


It should be understood that the foregoing disclosure and description of the present invention are illustrative and explanatory thereof and various changes in the size, shape and materials as well as in the description of the preferred embodiment may be made without departing from the spirit of the invention.

Claims
  • 1. A system for the securement of tissue comprising: a) a suture comprising a distal end and a proximal end, the distal end further comprising a distal connector and the proximal end further comprising a proximal connector;b) a needle comprising a proximal end and a distal end, the distal end further comprising a tissue piercing surface and the proximal end comprising a connector, the connector being releasably engageable with the distal connector of the suture; andc) a linear tissue passer comprising a proximal end and a distal end, the distal end directly releasably engageable with the distal and proximal connectors of the suture.
  • 2. The system of claim 1, wherein distal or proximal connectors of the suture is selected form the group of connectors consisting of an eyelet, a barb, a hook and a male detent.
  • 3. The system of claim 2, wherein the connectors of the suture is a conical barb or a flat barb.
  • 4. The system of claim 1, wherein the connector of the needle is selected from the group consisting of an eyelet, a barb, a hook and a male detent.
  • 5. The system of claim 4, wherein the barb is a conical barb or flat barb.
  • 6. The system of claim 1, wherein the distal end of the tissue passer comprises a geometry selected form the group consisting of an eyelet, a barb, a hook, and a male detent.
  • 7. The system of claim 1, wherein the distal and proximal suture connectors are eyelets, the proximal end of the needle and the distal end of the tissue passer comprises male detents releasably engageable with the eyelets of the suture.
  • 8. The system of claim 7, wherein the distal end of the tissue passer comprises a barb releasably engageable with the eyelets of the suture.
  • 9. The system of claim 7, wherein the distal end of the tissue passer comprises a hook releasably engageable with the eyelets of the suture.
  • 10. The system of claim 1, wherein the suture is a multifilament suture.
  • 11. The system of claim 1, wherein the distal or proximal connectors of the suture is selected from the group of connectors consisting of flat barbs, conical barbs and magnets.
  • 12. The system of claim 1, wherein one or both of the distal or proximal connectors of the suture are eyelets formed by bending back an end of the suture and knotting the end of the suture to form the eyelet.
  • 13. The system of claim 10, wherein one or both of the distal or proximal connectors of the multifilament suture are eyelets formed by bending back an end of the multifilament suture and splicing the end into and among the filaments of the suture at a distance sufficient from the end of the suture to form the eyelet.
US Referenced Citations (220)
Number Name Date Kind
2705492 Chandler Apr 1955 A
3123077 Alcamo Mar 1964 A
3378010 Codling et al. Apr 1968 A
4024855 Bucalo May 1977 A
4069825 Akiyama Jan 1978 A
4091816 Elam May 1978 A
4290763 Hurst Sep 1981 A
4523584 Lynch Jun 1985 A
4557264 Hinsch Dec 1985 A
4839215 Starling et al. Jun 1989 A
4881939 Newman Nov 1989 A
4950285 Wilk Aug 1990 A
5053047 Yoon Oct 1991 A
5067485 Cowen Nov 1991 A
5123913 Wilk et al. Jun 1992 A
5192271 Kalb et al. Mar 1993 A
5192274 Bierman Mar 1993 A
5269783 Sander Dec 1993 A
5284161 Karell Feb 1994 A
5311028 Glavish May 1994 A
5393984 Glavish Feb 1995 A
5483077 Glavish Jan 1996 A
5484444 Braunschweiler et al. Jan 1996 A
5485444 Kühn et al. Jan 1996 A
5609559 Weitzner Mar 1997 A
5683417 Cooper Nov 1997 A
5704895 Scott et al. Jan 1998 A
5792067 Karell Aug 1998 A
5843077 Edwards Dec 1998 A
5931855 Buncke Aug 1999 A
6161541 Woodson Dec 2000 A
6190401 Green et al. Feb 2001 B1
6241747 Ruff Jun 2001 B1
6250307 Conrad et al. Jun 2001 B1
6348156 Vishnoi et al. Feb 2002 B1
6408851 Karell Jun 2002 B1
6431174 Knudson et al. Aug 2002 B1
6432437 Hubbard Aug 2002 B1
6457472 Schwartz et al. Oct 2002 B1
6513530 Knudson et al. Feb 2003 B2
6523542 Knudson et al. Feb 2003 B2
6578580 Conrad et al. Jun 2003 B2
6589549 Shih et al. Jul 2003 B2
6599310 Leung et al. Jul 2003 B2
6627600 Boutignon Sep 2003 B2
6634362 Conrad et al. Oct 2003 B2
6638284 Rousseau et al. Oct 2003 B1
6716251 Asius et al. Apr 2004 B1
6742524 Knudson et al. Jun 2004 B2
6755868 Rousseau Jun 2004 B2
6800082 Rousseau Oct 2004 B2
6899105 Krueger et al. May 2005 B2
6955172 Nelson et al. Oct 2005 B2
6981944 Jamiolkowski et al. Jan 2006 B2
7017582 Metzger et al. Mar 2006 B2
7056331 Kaplan et al. Jun 2006 B2
7135189 Knapp Nov 2006 B2
7146981 Knudson et al. Dec 2006 B2
7166570 Hunter et al. Jan 2007 B2
7213599 Conrad et al. May 2007 B2
7237554 Conrad et al. Jul 2007 B2
7261702 Alexandre et al. Aug 2007 B1
7288075 Parihar et al. Oct 2007 B2
7297102 Smith et al. Nov 2007 B2
7322993 Metzger et al. Jan 2008 B2
7337781 Vassallo Mar 2008 B2
7360432 Lehtonen Apr 2008 B2
7360542 Nelson et al. Apr 2008 B2
7367340 Nelson et al. May 2008 B2
7401611 Conrad et al. Jul 2008 B2
7442389 Quelle et al. Oct 2008 B2
7601164 Wu Oct 2009 B2
7669603 Knudson et al. Mar 2010 B2
7806908 Ruff Oct 2010 B2
7850894 Lindh, Sr. et al. Dec 2010 B2
7857829 Kaplan et al. Dec 2010 B2
7888119 Sugaya et al. Feb 2011 B2
8142422 Makower et al. Mar 2012 B2
8307831 Rousseau Nov 2012 B2
8413661 Rousseau et al. Apr 2013 B2
8632488 Rousseau Jan 2014 B2
8800567 Weadock et al. Aug 2014 B2
20010037133 Knudson et al. Nov 2001 A1
20020144685 Ivanovich et al. Oct 2002 A1
20030004579 Rousseau et al. Jan 2003 A1
20030034312 Unger et al. Feb 2003 A1
20030149445 Knudson et al. Aug 2003 A1
20030149447 Morency et al. Aug 2003 A1
20030149488 Metzger et al. Aug 2003 A1
20030176875 Anderson et al. Sep 2003 A1
20040020492 Dubrul et al. Feb 2004 A1
20040020498 Knudson et al. Feb 2004 A1
20040028676 Klein et al. Feb 2004 A1
20040044366 Bonutti et al. Mar 2004 A1
20040102796 Hill et al. May 2004 A1
20040139975 Nelson et al. Jul 2004 A1
20040144395 Evans et al. Jul 2004 A1
20040147811 Diederich et al. Jul 2004 A1
20040149290 Nelson et al. Aug 2004 A1
20040153127 Gordon et al. Aug 2004 A1
20040231678 Fierro Nov 2004 A1
20050038472 Furst Feb 2005 A1
20050082452 Kirby Apr 2005 A1
20050092334 Conrad et al. May 2005 A1
20050115572 Brooks et al. Jun 2005 A1
20050121039 Brooks et al. Jun 2005 A1
20050126563 van de Burg et al. Jun 2005 A1
20050159637 Nelson et al. Jul 2005 A9
20050165352 Henry et al. Jul 2005 A1
20050199248 Pflueger et al. Sep 2005 A1
20050203576 Sulamanidze et al. Sep 2005 A1
20050251255 Metzger et al. Nov 2005 A1
20050267321 Shadduck Dec 2005 A1
20050267531 Ruff et al. Dec 2005 A1
20050267532 Wu Dec 2005 A1
20050267571 Spence et al. Dec 2005 A1
20050268919 Conrad et al. Dec 2005 A1
20050279365 Armijo et al. Dec 2005 A1
20060005843 Nelson et al. Jan 2006 A9
20060079935 Kolster Apr 2006 A1
20060083767 Deusch et al. Apr 2006 A1
20060093644 Quelle et al. May 2006 A1
20060150986 Roue et al. Jul 2006 A1
20060185673 Critzer et al. Aug 2006 A1
20060206197 Morsi Sep 2006 A1
20060207608 Hirotsuka et al. Sep 2006 A1
20060207612 Jackson et al. Sep 2006 A1
20060228391 Seyedin et al. Oct 2006 A1
20060241339 Cook et al. Oct 2006 A1
20060266369 Atkinson et al. Nov 2006 A1
20060289015 Boucher et al. Dec 2006 A1
20070000497 Boucher et al. Jan 2007 A1
20070005109 Popadiuk et al. Jan 2007 A1
20070005110 Collier et al. Jan 2007 A1
20070102004 Nelson et al. May 2007 A1
20070102010 Lemperle et al. May 2007 A1
20070110788 Hissong et al. May 2007 A1
20070119463 Nelson et al. May 2007 A1
20070123996 Sugaya et al. May 2007 A1
20070142700 Fogarty et al. Jun 2007 A1
20070144531 Tomas et al. Jun 2007 A1
20070144534 Mery et al. Jun 2007 A1
20070144535 Hegde et al. Jun 2007 A1
20070144539 Dineen et al. Jun 2007 A1
20070190108 Datta et al. Aug 2007 A1
20070204866 Conrad et al. Sep 2007 A1
20070209665 Gillis et al. Sep 2007 A1
20070227545 Conrad et al. Oct 2007 A1
20070233276 Conrad et al. Oct 2007 A1
20070246052 Hegde et al. Oct 2007 A1
20070256693 Paraschac et al. Nov 2007 A1
20070257395 Lindh et al. Nov 2007 A1
20070261701 Sanders Nov 2007 A1
20070267027 Nelson et al. Nov 2007 A1
20070270631 Nelson et al. Nov 2007 A1
20070272257 Nelson et al. Nov 2007 A1
20070288057 Kuhnel Dec 2007 A1
20070295338 Loomas et al. Dec 2007 A1
20070295340 Buscemi Dec 2007 A1
20080023012 Dineen et al. Jan 2008 A1
20080035158 Pflueger et al. Feb 2008 A1
20080035160 Woodson et al. Feb 2008 A1
20080053461 Dineen et al. Mar 2008 A1
20080066764 Paraschac et al. Mar 2008 A1
20080066765 Paraschac et al. Mar 2008 A1
20080066766 Paraschac et al. Mar 2008 A1
20080066767 Paraschac et al. Mar 2008 A1
20080066769 Dineen et al. Mar 2008 A1
20080078411 Buscemi et al. Apr 2008 A1
20080146868 Henri Robert et al. Jun 2008 A1
20080167614 Tolkowsky et al. Jul 2008 A1
20080199824 Hargadon Aug 2008 A1
20080208265 Frazier et al. Aug 2008 A1
20080221684 Nelson et al. Sep 2008 A1
20080312688 Nawrocki et al. Dec 2008 A1
20090025734 Doelling et al. Jan 2009 A1
20090078411 Kenison et al. Mar 2009 A1
20090165803 Bhat et al. Jul 2009 A1
20090299472 Huang Dec 2009 A1
20100023055 Rousseau Jan 2010 A1
20100024830 Rousseau et al. Feb 2010 A1
20100030011 Weadock et al. Feb 2010 A1
20100037901 Rousseau et al. Feb 2010 A1
20100049227 Hegde et al. Feb 2010 A1
20100080791 Rousseau et al. Apr 2010 A1
20100106246 Rousseau et al. Apr 2010 A1
20100108077 Lindh et al. May 2010 A1
20100132719 Jacobs et al. Jun 2010 A1
20100137794 Knudson et al. Jun 2010 A1
20100137905 Weadock et al. Jun 2010 A1
20100158854 Puisais Jun 2010 A1
20100163056 Tschopp et al. Jul 2010 A1
20100211184 Rousseau et al. Aug 2010 A1
20100234794 Weadock et al. Sep 2010 A1
20100234946 Rousseau Sep 2010 A1
20100256443 Griguol Oct 2010 A1
20100294284 Hohenhorst et al. Nov 2010 A1
20100319710 Sharkawy et al. Dec 2010 A1
20110054522 Lindh et al. Mar 2011 A1
20110100376 Rousseau May 2011 A1
20110100377 Weadock et al. May 2011 A1
20110100378 Rousseau May 2011 A1
20110144558 Rousseau Jun 2011 A1
20110174315 Zhang et al. Jul 2011 A1
20110178439 Irwin et al. Jul 2011 A1
20110238111 Frank Sep 2011 A1
20110245850 Cheng et al. Oct 2011 A1
20110282386 Friedrich Nov 2011 A1
20120123449 Schaller et al. May 2012 A1
20120160249 Garrett Jun 2012 A1
20120245629 Gross et al. Sep 2012 A1
20130074849 Rousseau et al. Mar 2013 A1
20130098371 Rousseau et al. Apr 2013 A1
20130103078 Crovella et al. Apr 2013 A1
20130118505 Rousseau et al. May 2013 A1
20130133669 Rousseau May 2013 A1
20130150872 Rousseau Jun 2013 A1
20130174857 Rousseau et al. Jul 2013 A1
20130186412 Weadock et al. Jul 2013 A1
20130319427 Sung et al. Dec 2013 A1
Foreign Referenced Citations (66)
Number Date Country
2465680 Dec 2001 CN
201029957 Mar 2008 CN
102198010 Sep 2011 CN
102271624 Dec 2011 CN
10245076 Apr 2004 DE
2145587 Jan 2010 EP
2386252 Nov 2011 EP
2517633 Oct 2012 EP
2651113 Mar 1991 FR
7-500386 Jan 1995 JP
11-514266 Dec 1999 JP
2001-145646 May 2001 JP
2003265621 Sep 2003 JP
2005-529643 Oct 2005 JP
2006-508708 Mar 2006 JP
2006-517115 Jul 2006 JP
2007-512090 May 2007 JP
2007-313337 Dec 2007 JP
2008-526286 Jul 2008 JP
2008-529608 Aug 2008 JP
2009-006090 Jan 2009 JP
2010-017560 Jan 2010 JP
2011-530385 Dec 2011 JP
2005447 Jan 1994 RU
2202313 Apr 2003 RU
927236 May 1982 SU
1697792 Dec 1991 SU
WO 9713465 Apr 1997 WO
WO 9900058 Jan 1999 WO
WO 0066050 Nov 2000 WO
WO 0121107 Mar 2001 WO
WO 03075792 Sep 2003 WO
WO 03096928 Nov 2003 WO
WO 2004016196 Feb 2004 WO
WO 2004020492 Mar 2004 WO
WO 2004021869 Mar 2004 WO
WO 2004021870 Mar 2004 WO
WO 2004060311 Jul 2004 WO
WO 2004084709 Oct 2004 WO
WO 2004103196 Dec 2004 WO
WO 2005046554 May 2005 WO
WO 2005051292 Jun 2005 WO
WO 2005082452 Sep 2005 WO
WO 2005122954 Dec 2005 WO
WO 2006012188 Feb 2006 WO
WO 2006072571 Jul 2006 WO
WO 2006108145 Oct 2006 WO
WO 2007056583 May 2007 WO
WO 2007075394 Jul 2007 WO
WO 2007132449 Nov 2007 WO
WO 2007134005 Nov 2007 WO
WO 2007146338 Dec 2007 WO
WO 2007149469 Dec 2007 WO
WO 2008042058 Apr 2008 WO
WO 2008063218 May 2008 WO
WO 2008118913 Oct 2008 WO
WO 2009023256 Feb 2009 WO
WO 2009036094 Mar 2009 WO
WO 2010019376 Feb 2010 WO
WO 2010035303 Apr 2010 WO
WO 2010051195 May 2010 WO
WO 2010065341 Jun 2010 WO
WO 2012004758 Jan 2012 WO
WO 2012041205 Apr 2012 WO
WO 2012064902 May 2012 WO
WO 2012170468 Dec 2012 WO
Non-Patent Literature Citations (58)
Entry
Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority or the Declaration mailed on Feb. 3, 2010 for PCT/US2009/051921; International Filing Date: Jul. 28, 2009.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority or the Declaration mailed on May 25, 2010 for PCT/US2010/023152; International Filing Date: Apr. 2, 2010.
International Search Report dated Nov. 4, 2009 for International Patent Application No. PCT/US2009/052126.
International Search Report dated Dec. 21, 2009 for International Patent Application No. PCT/US2009/057661.
International Search Report dated Dec. 22, 2009 for International Patent Application No. PCT/US2009/061223.
International Search Report dated Dec. 29, 2009 for International Patent Application No. PCT/US2009/061455.
International Search Report dated Jan. 21, 2010 for International Patent Application No. PCT/US2009/052110.
International Search Report dated Apr. 29, 2010 for International Patent Application No. PCT/US2009/065293.
International Search Report dated May 25, 2010 for International Patent Application No. PCT/US2010/023152.
International Search Report dated May 25, 2010 for International Patent Application No. PCT/US2010/025778.
International Search Report dated Jan. 14, 2011 for International Patent Application No. PCT/US2010/052628.
International Search Report dated Jan. 20, 2011 for International Patent Application No. PCT/US2010/052644.
International Search Report dated Jan. 24, 2011 for International Patent Application No. PCT/US2010/052649.
International Search Report dated Feb. 28, 2011 for International Patent Application No. PCT/US2010/059673.
International Search Report dated Apr. 9, 2013 for International Patent Application No. PCT/US2012/061569.
International Search Report dated Apr. 2, 2013 for International Patent Application No. PCT/US2012/067708.
International Search Report dated Oct. 2, 2013 re: PCT/US2013/043238.
International Search Report dated May 24, 2013 for International Patent Application No. PCT/US2012/066011.
Written Opinion dated Nov. 27, 2012 for International Patent Application No. PCT/US2012/056577.
MacMillan Dictionary, Fiber, MacMillan Publisher, Limited 2009-2014.
International Search Report re: PCT/US2012/0565677 dated Nov. 27, 2012.
International Preliminary Report on Patentability dated Feb. 15, 2011 for International Patent Application No. PCT/US2009/051921.
International Preliminary Report on Patentability dated Apr. 1, 2014 for International Patent Application No. PCT/US2012/056577.
International Preliminary Report on Patentability dated Jun. 10, 2014 for International Patent Application No. PCT/US2012/067708.
International Preliminary Report on Patentability dated Dec. 2, 2014 for International Patent Application No. PCT/US2013/043238.
International Search Report dated Mar. 2, 2010 for International Patent Application No. PCT/US2009/051921.
Cole et al., “Snoring: A Review and a Reassessment”, J. of Otolaryngology, vol. 24, No. 5 pp. 303-306 (1995).
Database WPI Week 198312, Thomson Scientific, London, GB; AN 1983-D9513K XP002693421, -& SU 927 236 A1 (Petrozazodsk Univ) May 15, 1982 abstract (see figures 7 & 8).
Friedman et al., “A System and Method for Inserting a Medical Device for Treatment of Sleep Apnea via the Nasal Passage, and Device Therefor”, Dec. 29, 2008, U.S. Appl. No. 61/203,758, p. 8 & p. 6/8.
Harries et al., “The Surgical treatment of snoring”, J. of Laryngology and Otology, vol. 110, Issue 12 pp. 1105-1106 (1996).
Huang et al., “Biomechanics of snoring”, Endeavour, vol. 19(3): pp. 96-100 (1995).
Medtronic AIRvance System for Obstructive Sleep Apnea. http.//www.medtronic.com/for-healthcare-professionals/products-therapies/ear-nose-throat/sleep-disordered-breathing-products/airvance-system-for-obstructive-sleep-apnea/index.htm.
Pang, Kenny et al., “Tongue Suspension Suture in Obstructive Sleep Apnea”, Operative Techniques in Otolaryngology, vol. 17, No. 4, pp. 252-256 (2006).
Repose Genioglossus Advancement, INFLUENT Medical, www.influ-ent.com, 1 page (2008).
Schleef et al., “Cytokine Activation of Vascular Endothelium, Effects on Tissue-Type 1 Plasminogen Activator Inhibitor” The J. of Biological Chem., vol. 263, No. 12, pp. 5797-5803 (1988).
Schwab et al., “Upper airway and soft tissue changes induced by CPAP in normal subject”, Am. J. Respit. Crit. Care Med., vol. 154, No. 4 pp. 1106-1116 (1996).
Schwartz et al., “Effects of electrical stimulation to the soft palate on snoring and obstructive sleep apnea”, J. Prosthetic Dentistry, vol. 76 pp. 273-281 (1996).
Shamsuzzaman et al., “Obstructive Sleep Apnea; Implications for Cardiac and Vascular Disease”, JAMA vol. 290, No. 14 pp. 1906-1914 (2003).
Teles et al., “Use of Palatal Lift Prosthesis on Patient Submitted to Maxillectomy: A Case Report”, Applied Cancer Res. vol. 25(3), pp. 151-154 (2005).
The Advance System, Aspire Medical, Inc. www.aspiremedical.com, 3 pp (2008).
The Pillar Procedure, Restore Medical, Inc. www.restoremedical.com, 2 pp (2008).
Vicente et al., “Tongue-Base Suspension in Conjunction with Uvulopapatopharyngoplasty for Treatment of Severe Obstructive Sleep Apnea: Long-term Follow-Up Results”, The Laryngoscope, vol. 116 pp. 1223-1227 (2006).
Wassmuth et al., “Cautery-assisted palatal stiffening operation for the treatment of obstructive sleep apnea syndrome”, Otolaryngology—Head and Neck Surgery, vol. 123, pp. 55-60 (2000).
Wiltfang et al., “First results on daytime submandibular electrostimulation of suprahyoidal muscles to prevent night-time hypopharyngeal collapse in obstructive sleep apnea syndrome”, Intl J. of Oral & Maxillofacial Surgery vol. 28 pp. 21-25 (1999).
International Preliminary Report on Patentability dated Feb. 1, 2011 for International Patent Application No. PCT/US2009/052110.
International Preliminary Report on Patentability dated Feb. 1, 2011 for International Patent Application No. PCT/US2009/052126.
International Preliminary Report on Patentability dated Apr. 26, 2011 for International Patent Application No. PCT/US2009/061223.
International Preliminary Report on Patentability dated May 3, 2011 for International Patent Application No. PCT/US2009/061455.
International Preliminary Report on Patentability dated Jun. 7, 2011 for International Patent Application No. PCT/US2009/065293.
International Preliminary Report on Patentability dated Aug. 23, 2011 for International Patent Application No. PCT/US2010/023152.
International Preliminary Report on Patentability dated Sep. 20, 2011 for International Patent Application No. PCT/US2010/025778.
International Preliminary Report on Patentability dated May 1, 2012 for International Patent Application No. PCT/US2010/052628.
International Preliminary Report on Patentability dated May 1, 2012 for International Patent Application No. PCT/US2010/052644.
International Preliminary Report on Patentability dated May 1, 2012 for International Patent Application No. PCT/US2010/052649.
International Preliminary Report on Patentability dated Jun. 19, 2012 for International Patent Application No. PCT/US2010/059673.
International Preliminary Report on Patentability dated Apr. 29, 2014 for International Patent Application No. PCT/US2012/061569.
International Preliminary Report on Patentability dated Jun. 3, 2014 for International Patent Application No. PCT/US2012/066011.
Nordgard, S. et al ‘One-year results: palatal implants for the treatment of obstructive sleep apnea’ Otolaryngology Head Neck Surg. May 2007; 136(5): 818-22.
Related Publications (1)
Number Date Country
20140261452 A1 Sep 2014 US
Continuations (1)
Number Date Country
Parent 13247713 Sep 2011 US
Child 14291784 US